Objective: There is an increasing incidence of Acinetobacter species causing serious hospital acquired infections such as blood stream infections (BSI), catheter associated urinary tract infections (CAUTI) and lower respiratory tract infections(LRTI) with high mortality rate of 30-75% in patients having long hospital stay especially in critical care units (CCUs). During the past decade, multi drug resistant Acinetobacter isolates have presented a real challenge to clinicians and are posing difficulties in treatment. Carbapenem-resistant Acinetobacter species particularly A. baumannii, represent a growing public health concern, since they often confer resistance to other critically important antimicrobials.
INTRODUCTION
There is an increasing incidence of Acinetobacter species causing serious hospital acquired infections such as blood stream infections(BSIs), catheter associated urinary tract infections(CAUTIs), lower respiratory tract infections(LRTIs) and skin & soft tissue infections with high mortality rate of 30-75% in patients with long hospital stay especially in critical care units (CCUs) [1] .
With the rise of incidence of carbapenemresistant Acinetobacter species, there is critical need to discover safe and effective therapeutic strategies. Apart from colistin the treatment options left to treat carbapenem-resistant Acinetobacter species are tigecycline, polymyxin B, fosfomycin, sulbactam as monotherapy [2] .
Usage of polymyxins has been increasing in trends, the only therapeutic options for these carbapenem-resistant Acinetobacter species infections. The limitations related to polymyxins usage are irrelevant dosage, promising adverse effects (nephrotoxicity) and emergence of resistance [2] .
As various therapeutic approaches have been contemplated like combination therapy through in-vitro ( in laboratory), in-vivo ( animal model) and clinical trials, should be included in therapeutic regime as the fortitude for cure of infections caused by isolates which are colistinsusceptible as well as colistin-resistant [3] .
In this present study, we have used four antibiotic combinations with three different methods for Carbapenem-resistant Acinetobacter species infections. Although only a few study have been done in India on synergy, Anandan et al, from CMC Vellore has published in-vitro synergy based on colistin combination with sulbactam and meropenem on MDR Acinetobacter species isoated from ventilator associated pneumonia. This study showed commendable synergy by time kill analysis with combination of sulbactam & meropenem. [4] Our study would help us to illustrate the appropriateness of synergy testing to anticipate the action of specific antimicrobials combinations against carbapenem-resistant Acinetobacter species, which can be further used by clinicians in treatment.
METHODS
The study was planned and experimental conducted from January 2016 to June 2017 in the department of Microbiology, Government Medical College & Hospital, Chandigarh, India. A total of 100 non repeated strains of Acinetobacter species were isolated from the various samples received from ICU & wards of our tertiary care hospital. Ethical clearance was taken from the Ethical committee of Govt. Medical College and Hospital, Chandigarh.
Isolation and susceptibility testing
Acinetobacter species was identified using standard microbiological methods. Antimicrobial susceptibility testing of Acinetobacter isolates was done using Kirby Bauer disk diffusion method according to Clinical Laboratory Standards Institute (CLSI) guidelines 2016 [5] .
MIC determination
Additionally for all those imipenem resistant isolates by disk diffusion method, MIC values were determined by Etest (Bio Merieux) and then Broth Microdilution Method (BMD). The MIC determination was done for the following antimicrobials used in combinations in our studycolistin, meropenem, tigecycline, imipenem, polymyxin B, azithromycin, doripenem, sulbactam. The antimicrobials labeled as resistant/sensitive based on their breakpoints given by CLSI 2016. [5] 
Synergy testing by Epsilometric test, (Etest)
Mueller-Hinton Agar (MHA, Hi Media) was inoculated with 0.5 Mc Farland suspensions of study isolates. This method was performed conceding to the method interpreted by Balaji V., et al, the fixed ratio Epsilometric method [2] .
Interpretation: The interpretation of AMA combinations methods were determined by observing the MIC of individual drugs; drug A, which were active drugs in combinations(colistin, tigecycline, sulbactam and polymyxin B) and the MIC of drug B, which were resistant for the study isolates (meropenem, imipenem, doripenem, and azithromycin) after prediffusion of active drug in the medium. Then synergy was determined as follows by combined MIC by the formula [7] .
If MIC of combined drug A+B is reduced by 3 fold dilutions as compared to MIC of drug A (active) the result was considered as 'Synergistic'.
Synergy testing by Broth Micro Dilution Checker-Board (MBD)
Test methods are based on standard CLSI M7-A8 broth dilution susceptibility methods [8] . Antimicrobial stock solutions were prepared according to manual given in CLSI M7-A8 in the appropriate diluents as indicated in CLSI [5] . 
Synergy interpretation by Broth micro dilution method
The Fractional Inhibitory Concentration Index (FICI) was estimated to determine synergy by implicating subsequent equation- [7] FICI= FIC A +FIC B 
Synergy testing by Time-kill Analysis
To perform the time-kill assay, there are various specifications must be known. We calculated the MIC of the each antimicrobial drug in combination for the Acinetobacter isolates of interest by a Broth Micro dilution method [9] .
Procedure
The 
Interpretation
Results were interpreted as individual agent MIC and combined MICs as follows [9] :
We determined the log10 CFU/ml for individual agents and the decreased colony counts were compared with the growth control at sample times. Then we determined the difference in log10 Colony forming Unit (CFU) /ml between the most vital antimicrobial drug individually at 1/4th MIC and the combination of drugs at 1/4th or 1/8th MIC. Synergism is usually defined as decrease in Colony forming units by more than 2-log10 CFU/ml by the combination of drugs as compared with the most active individual drug.
Quality control strains
For MIC assurance quality control strains were included in the study; Escherichia coli (ATCC 25922) and Pseudomonas aeruginosa (ATCC 27853).
In addition to microbiological testing the clinical data of the patients whose strains are included in the study have been recorded.
RESULTS
A total of 100 non repeated strains of Acinetobacter species were isolated from various clinical samples (blood culture, pus aspirate, Bronco-alveolar lavage, ascitic fluid, tracheal aspiration, tissue, high vaginal swab) during study period. The Acinetobacter species were identified on the basis of colony characteristics, staining properties and biochemical reactions.
Antibiotic susceptibility
The observations were made on antimicrobial sensitivity methods using Kirby Bauer diskdiffusion method for the drugs advocated by CLSI 2016 (Table 1) . To ascertain the breakpoints for these Acinetobacter isolates CLSI guidelines-2016 were referred, BSAC for tigecycline and sulbactam as no CLSI breakpoints (Table 2) 
MIC determination
MIC determination was done using Etest and then Broth Microdilution method (BMD) for all the antimicrobial agents used in the study.
MIC dtermination by Etest
MIC was determined using Etest for individual drugs used in combination shown in (Table 3) . Most of the strains showed high MIC values (resistant) for meropenem, imipenem, doripenem and azithromycin.
MIC determination by BMD method
MIC determination was also done by BMD method for all drugs used in the study because MIC determined by Etest was not reliable and upto the mark as a limited MIC values are graded on the strips which can be calculated & for further reading of MIC values BMD method is more reliable as the accurate value can be calculated by it (Table 4 ).
Synergy testing
Results with different combinations, using three methods Etest, BMD and the gold standard TKA are as follows;
Synergy testing interpretation using Etest with all four combinations
Firstly synergy testing by Etest with different antibiotics combinations showed different interactions on hundred Acinetobacter isolates (Table 5) showing Etest with meropenem and colistin combination.
Synergy testing interpretation using BMD with all four combinations;
The resultant interpretation of BMD method was done using Fractional Inhibitory Concentration Values (FICI) for each isolates with all combinations [7] . It was found that with the combination meropenem+colistin, second combination imipenem+ tigecycline and third combination azithromycin+ polymyxin B showed synergistic results but with the forth combination doripenem+ sulbactam, none of the isolate showed synergy (Table 6 ).
Synergy testing interpretation using time kill assay with all four combinations;
In our study, TKA was performed only on those Acinetobacter isolates, which showed synergy with both Etest and Broth Micro dilution method. It was found that with the combination of meropenem + colistin, 53% isolates showed synergy. The second combination imipenem+ tigecycline, 52% isolates showed synergy. Third combination azithromycin + polymyxin B, 48% isolates showed synergy at different timings with respective MICs.
With the combination of doripenem+sulbactam synergy was not detected with any of the isolate. by Broth microdiilution method (Table 7) . Table 8 .
Third combination doripenem + sulbactam showed 86% synergy with Etest but did not showed synergy by BMD.
Outcome
The antibiotic regimen given to the patients and their outcome was correlated according to the therapy received. It was just an observation what antibiotics they had recieved during treatment for these carbapenem-resistant Acinetobacter isolates to have an idea that combination therapy or monotherapy which have better outcome.
A total of hundred patients were entailed in our research, those were infected with Acinetobacter species. Consents have been taken before 
MIC range (mg/L) MER (n) IMP (n) DOR (n) AZI (n) COL (n) TIG (n) SUL (n) PB (n)

DISCUSSION
In the last few years, carbapenem-resistant Acinetobacter species has been labeled as a "red alert" human microorganism, triggering distress amongst the health care professionals, due to its emergence of antibiotic resistance pattern [10] .
Over the last decade in Europe and worldwide, Acinetobacter species especially Acinetobacter baumannii has become increasingly resistant to carbapenems drugs, a broad spectrum betalactam group of antibiotics. It is an important therapeutic option for patients infected with multi drug-resistant gram-negative bacteria [11] . In our research the first, colistin-meropenem combination revealed commendable synergy by using Etest, BMD method which was confirmed by TKA. It was found that all the isolates showed synergy with TKA and synergy with this combination was statistically convincing (p<0.05).
An analysis done in the Medical Center, Beirut, manifested that the combination experiments between colistin & carbapenem showed very high degree of addition by using methods used in our study (Etest, BMD, TKA) [12] . Another study conducted by LeMinh et al, in Vietnam, showed synergistic rates with colistinmeropenem and colistin-imipenem respectively 68% and 36% [13] . Justin RL, showed the combination with colistin & carbapenems has been studied earlier where authors conveyed that microorganism re-growth can be stopped or regulated. The resultant MIC of colistin also decreased by two-fold. This is very much suggestive of using lower dosage of colistin in treatment with minimal of adverse effects. Also, above study revealed significantly additive effect of colistin and carbapenem combinations (p < 0.05) [14] .
The second combination used in our study i.e. imipenem & tigecycline showed a good synergistic effect by all the three methods described in study. The result was significant statistically (p<0.05). So the combination of tigecycline+imipenem is also a good choice for carbapenem-resistant Acinetobacter isolates.
A study performed in-vitro synergy test by D'Arezzo et al, showed that by using BMD and TKA methods with the combination of imipenem + tigecycline, found synergistic interaction (MICs for tigecycline (0.5 mg/L) and imipenem(16 mg/L), respectively) in Acinetobacter species isolates [15] . The author concluded that, combination therapy with tigecycline & imipenem could depicted a better regimen to fight with resistant strains to both these drugs individually. Another study done by Kuo & Lee et al showed that combination therapy (imipenem + tigecycline) possesses synergistic activity that is effect could be more than addition of two antimicrobials individually. This effect has been shown to increase positive outcomes in the treatment of immunocompromised patients infected with Carbapenem-Resistant Acinetobacter (CRA)-related infections [16, 17] . Pachon Ibanez et al, showed that tigecycline is a bacteriostatic agent, used to treat CRA infections and tigecycline was more active than imipenem against CRA. The author has concluded that to ameliorate the clinical condition of a patient tigecycline is suitable to combine with another antimicrobial drug like carbapenems [18] .
To culminate the results of in-vitro study combination of carbapenem and tigecycline can be included in therapeutic options and assure to be advantageous for the cure of CRA infections.
In concern of third combination azithromycin & polymyxin B, our study showed good results by all the three methods. By using Etest, and BMD method this combination also showed synergy TKA was done to confirm the synergistic results and displayed 100% corroborative results with BMD method. The resultant synergy with both of these methods showed statistically significance (p<0.05). A study done by Nageeb et al, detected synergy by experimenting Epsilometric test between polymyxin and azithromycin (100% isolates) and in 66% isolates it was done by TKA with the same combination. Author concluded that azithromycin and polymyxin B combination is justifiable and advised. It may be converted into convenient curative strategy by synergism between two or more drugs results in lowering the effective MIC values with addition to their pharmacological and biological effects to determine the actual therapeutic dosage of these antimicrobial in combinations for clinical practice [19] . Manikal et al interrogated synergism method i.e. Broth micro-dilution with polymyxin and azithromycin combinations in contrary to Acinetobacter isolates belonging to distinct genotypes. They found approximately 80% resultant synergy with this combination and 20% isolates showed addition effect. Almost 8% of Acinetobacter isolates showing synergy with azithromycin and polymyxin combination were resistant to polymyxin [20] . Luber et al, conveyed that with Broth microdilution method, moreover the results were in favor of addition compared to Epsilometric method (p<0.05). This could be due to disparity in classical property between the liquid and the solid media that were used for these experiments in Broth microdilution and Etest respectively [21] .
In consideration to last combination i.e. doripenem and sulbactam, in our study we found synergy with doripenem and sulbactam combination by using Etest only but did not find synergy with MCB and time kill assay. The resultant synergism was not showed analytically significant (p=0.069). Elucidation could be that all study isolates in our study had higher MIC values for both sulbactam and doripenem so could not interact with each other in the effective way. As none of the drug contributed an active role for this combination against Acinetobacter isolates which was used in the study. [24] . The second drug, sulbactam was chosen as active drug because it expressed intrinsic bactericidal activity against MDR Acinetobacter isolates infections, as it inhibits the penicillin-binding proteins [25] . It is irreversible inhibitor of beta-lactamase producing organisms like Acinetobacter and does not allow enzymes to degrade the antibiotic [26] .
Related to outcome of patients, various studies across the world and few studies from India, suggested that combination therapy has several advantages over monotherapy with regard to mortality of critically ill patients [27] .
In our study there is not disagreement between both the groups with respect to their mortality (46% in double drug therapy vs. 45% in triple drug therapy). Since none of the patient in our study received monotherapy, therefore we could not compare monotherapy v/s combination therapy in regard to mortality of the patients. Hence probable reasons why even after giving combination therapy the patients had higher mortality were delayed appropriate antibiotic therapy, severity of clinical illness and associated co-morbidities like diabetes, hypertension, acute renal failure, cardiac disease and cancer.
Falagas et al., proposed a methodical review that combination therapy has offer a great correlative asset over single drug therapy clinically in survival of patients infected with carbapenem-resistant gram negative organisms [28] . An observational study done by Ghafur et al, from India, found that there was no remarkable distinction in mortality between single drug and two or three drug combinations in the patients infected with Acinetobacter and Pseudomonas bacteremia (n= 36) as well (P= 0.067), except in neutropenic patients, where combination therapy accomplished better outcome [29] .
Due to recurrent modification of antimicrobial treatment, outcome of this population might be challenging to assess the severely ill patients included in these studies. Besides, the results for specific combinations might vary among different studies due to dissimilarities in population of patients, co morbidities, treatment regime, dosage, durations, and strain-dependent factors. This data was just to have an idea that the clinician are using which two and three drug combinations more frequently and then once our results are available in formulating antibiotic policy for the Institute. In-vitro analysis of data suggests that combination therapeutic strategy can be adequate when microorganisms are Another review by Lisa Saiman, recommended, that in clinical practice, clinician start empirical antibiotic therapy before getting the result of antimicrobial sensitivity. If patient responded to that drug clinically, clinician would continue it. This is the promising implication for synergy testing and is applicable when a patient is failing to respond clinically to the treatment. However, synergy testing can be advisable to decide the treatment when a patient is not responding to antimicrobial agents, while the microorganisms are susceptible [30] .
To treat such infection caused by carbapenemresistant microorganisms, this study and analysis provide us navigation. To boost up the clinical events of these patients, we have a devious way to go, to ameliorate outcomes further.
The constraint of our study is that combination effects detected by Broth Micro dilution & time kill assay could not be analyzed with molecular methods. The mechanisms of resistance were not studied.
